Efectos de la COVID-19 en el consumo de antidepresivos en la provincia de Santa Cruz de Tenerife, Islas Canarias

  1. Mariana Sapino 1
  2. Alexis Oliva Martín 2
  3. Sandra Dévora Gutiérrez 1
  4. Susana Abdala Kuri 1
  1. 1 Departamento de Medicina Física y Farmacología, Facultad de Farmacia, Universidad de La Laguna, Tenerife, España. 2
  2. 2 Departamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna, Tenerife, España.
Revista:
Farmacéuticos comunitarios

ISSN: 1885-8619

Año de publicación: 2023

Volumen: 15

Número: 1

Páginas: 64-71

Tipo: Artículo

DOI: 10.33620/FC.2173-9218.(2023).07 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Farmacéuticos comunitarios

Objetivos de desarrollo sostenible

Resumen

Background: This work analyzed the impact of COVID-19 on antidepressant consumption during the first year of the pandemic (2020) taking as a baseline the prescribing trends during the previous 4 years (2016-2019). For this, the province of Santa Cruz de Tenerife and the 4 islands that make it up were taken as a geographical area. Methods: Sales data in community pharmacies were taken as an aggregated database. The dose per inhabitant and day was used as an indicator of consumption. Results: In the islands of EL Hierro and La Gomera, the increase in population does not in itself justify the relevant increases observed in the consumption of antidepressants and possibly COVID-19 and its consequences on the health of the population could be responsible for these increases. On the island of Tenerife, the increase in population could justify, to a large extent, the slight increase in consumption observed. The island of La Palma presents an increase of 1.40%, but lower than the expected value taking as baseline the prescribing trends in the last 4 years, despite an increase in population of 0,95%. All the islands present the same trends in the consumption of the different subgroups of antidepressants and active pharmaceutical ingredients, although with slight variations, with the exception of the island of La Palma which presents a statistically different behavior and trends. Conclusions: These differences could be related to the socio-sanitary and demographic characteristics of each of the islands.

Referencias bibliográficas

  • 1. Brooks KS, Webster KR, Smith EL, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020; 395:912-920. doi:https://doi.org/10.1016/S0140-6736(20)30460-8
  • 2. Chacón Fuertes F, Fernández Hermida JR, García Vera M. La psicología ante la pandemia de la COVID-19 en España. La respuesta de la organización colegial. Clín. Salud 2020; 31:119-123. doi:https://doi.org/10.5093/clysa2020a18
  • 3. Torales J, O’Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020; 66:317–320. doi:https://doi.org/10.1177/0020764020915212
  • 4. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom 2016; 85:270–288. doi:https://doi.org/10.1159/000447034
  • 5. Zhong W, Kremers HM, Yawn BP, Bobo WV, St Sauver JL, Ebbert JO. Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population. Arch Womens Ment Health 2014; 17:485–492. doi:https://doi.org/10.1007/s00737-014-0450-7
  • 6. Revet A, Montastruc F, Raynaud JP, Baricault B, Montastruc, Lapeyre-Mestre JL. Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. J. Clin. Psychopharmacol 2018; 38:327-335. doi:https://doi.org/10.1097/JCP.0000000000000891
  • 7. Wang C, Pan R, Wan, X, Tan, Y, Xu L, S Ho C, Ho RC. Immediate psychological responses and associated factors during the initial stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the general population in China. Int J Environ Res Public Health 2020; 17:1729. doi:https://doi.org/10.3390/ijerph17051729
  • 8. Cénat JM, Dalexis RD, Kokou-Kpolou CK, Mukunzi JN, Rousseau C. Social inequalities and collateral damages of the COVID-19 pandemic: when basic needs challenge mental health care. Int J Public Health 2020; 65:717-718. doi:https://doi.org/10.1007/s00038-020-01426-y
  • 9. Rodríguez Quiroga A, Buiza C, De Mon Álvares MA, Quintero J. COVID-19 y salud mental. Medicine 2020; 13:1285-1296. doi:https://doi.org/10.1016/j.med.2020.12.010
  • 10. Rodríguez Rey R, Garrido Hernansaiz H, Collado S. Psychological Impact and Associated Factors During the Initial Stage of the Coronavirus (COVID-19) Pandemic Among the General Population in Spain. Front Psychol 2020; 11: art.1540. doi:https://doi.org/10.3389/fpsyg.2020.01540
  • 11. Ruíz Fernández MD, Ramos Pichardo JD, Ibáñez Masero O, Cabrera Troya J, Carmona Rega MI, Ortega Galán A. Compassion fatigue, burnout, compassion satisfaction, and perceived stress in healthcare professionals during the COVID-19 health crisis in Spain. J Clin Nurs 2020; 29:4321-4330. doi:https://doi.org/10.1111/jocn.15469
  • 12. Halonen JI, Koskinen A, Varje P, Kouvonen A, Hakanen JJ, Väänänen A. Mental health by gender-specific occupational groups: profiles, risks and dominance of predictors. J. Affect. Disord 2018; 238:311-316. doi:https://doi.org/10.1016/j.jad.2018.06.007
  • 13. González López MC. Estudio de utilización de fármacos antidepresivos en el ámbito de la atención primaria de Almería [Tesis doctoral]. Almería: Universidad de Almería; 2015. https://dialnet.unirioja.es/servlet/tesis?codigo=222146
  • 14. Morrison J, Anderson MJ, Sutton M, Munoz-Arroyo R, McDonald S, Maxwell M, Power A, Smith M, Wilson P. Factors influencing variation in prescribing of antidepressants by general practices in Scotland. Br J Gen Pract 2009; 59: e25–e31. doi:https://doi.org/10.3399/bjgp09X395076
  • 15. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. Boletín Oficial del Estado, número 294, (6 de diciembre de 2018). Disponible en: https://www.boe.es/eli/es/lo/2018/12/05/3
  • 16. Instituto Nacional de Estadística (INE). España; 2020. Disponible en: https://www.ine.es
  • 17. Instituto Canario de Estadística (ISTAC). Islas Canarias; 2020. Disponible en: http://www.gobiernodecanarias.org/istac/
  • 18. World Health Organization (WHO) Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: OMS; 2019. Disponible en: https://www.whocc.no/atc_ddd_index
  • 19. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Disponible en: https://www.R-project.org.
  • 20. Balluerka Lasa N, Gómez Benito J, Hidalgo Montesinos D, Gorastiaga Manterola A, Espada Sánchez JP, Padilla García JL, Santed Germán MA. Las consecuencias psicológicas de la COVID-19 y el confinamiento. Servicio Publicaciones de la Universidad del País Vasco; 2020 Disponible en: https://www.ub.edu/web/ub/ca/menu_eines/noticies/docs/Consecuencias_psicologicas_COVID-19.pdf
  • 21. Hernández JF, Mantel Teeuwisse AK, Van Thiel GJ, Belitser SV, Warmerdam J, de Valk V, Raaijimakers JA, Pieters T. A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. PLoS ONE 2012; 7: e45515. doi:https://doi.org/10.1371/journal.pone.0045515
  • 22. Parabiaghi A, Franchi C, Tettamanti M, Barbato A, D’Avanzo B, Fortino I, Bortolotti A, Merlino L, Nobili A. Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur J Clin Pharmacol 2011; 67:1077–1083. doi:https://doi.org/10.1007/s00228-011-1054-z
  • 23. Ministerio de Sanidad de España (MSE). Consumo de medicamentos en recetas médicas dispensadas en oficinas de farmacia con cargo al Sistema Nacional de Salud según clasificación Anatómica-Terapéutica-Química (ATC);2022. Disponible en: https://www.sanidad.gob.es/profesionales/farmacia/ConsumoRecetasATC/home.htm
  • 24. Corada Prieto J. Consumo de antidepresivos en el País Vasco: análisis cuantitativo con perspectiva de género. Universidad del País Vasco; 2021. Disponible en: https://hdl.handle.net/10810/54644
  • 25. Oliva A, Armas N, Dévora S, Abdala S. Opioid use trends in Spain: the case of the island of La Gomera (2016–2019). Naunyn Schmiedebergs Arch. Pharmacol 2022; 395:217-226. doi:https://doi.org/10.1007/s00210-021-02193-0
  • 26. Martínez ER, Gisbert FJG, Martí IC. Delimitación de áreas rurales y urbanas a nivel local: demografía, coberturas del suelo y accesibilidad. Fundación BBVA, Informe de Economía y Sociedad primera edición; 2016. Disponible en: https://www.fbbva.es/publicaciones/delimitacion-de-areas-rurales-y-urbanas-a-nivel-local-demografia-coberturas-del-suelo-y-accesibilidad
  • 27. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 2015; 29:695-712. doi:https://doi.org/10.1007/s40263-015-0267-6
  • 28. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins J, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Loannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018; 391:1357–1366. doi:https://doi.org/10.1016/S0140-6736(17)32802-7
  • 29. Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor-controlled trials. BMJ 2010; 341:c4737. doi:https://doi.org/10.1136/bmj.c4737
  • 30. Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. Rev. psiquiatr. salud ment 2018; 11:48-59. doi:https://doi.org/10.1016/j.rpsm.2017.06.006
Fuente de los datos: Dialnet